Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High- Cutoff Filter Kim Dao, MD, Haithem Chtioui, MD, Yimin Lu, MD, Cody J. Peer, MS, PhD, William D. Figg, PharmD, FCP, Menno Pruijm, MD, Thierry Buclin, MD, Sébastien Kissling, MD American Journal of Kidney Diseases Volume 69, Issue 4, Pages 553-554 (April 2017) DOI: 10.1053/j.ajkd.2016.10.026 Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions
Figure 1 Predicted (continuous line) and measured (open circles) pomalidomide concentrations over time. HCO dialysis sessions are indicated by grey horizontal bars; pomalidomide doses (2mg), by open triangles. Predicted concentrations (with 2mg/d dosage) in the absence of dialysis denoted by dotted line. American Journal of Kidney Diseases 2017 69, 553-554DOI: (10.1053/j.ajkd.2016.10.026) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions